欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
C643人甲状腺癌细胞(STR鉴定)[套餐促销]
英文名:C643
货号:ZQ0321
价格:¥1350.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

C643人甲状腺癌细胞(STR鉴定)[套餐促销]

¥1350.00
+

C643人甲状腺癌细胞专用培养基

¥350.00 ¥450.00

配套完培,组合使用,省时省力

=

细胞套餐惊爆价

¥1700 ¥1950.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

C643人甲状腺癌细胞

货号

ZQ0321

产品介绍

C643细胞系由Mark等人于1987年从一名76岁男性间变性甲状腺癌的细针活检中建立。患者在确诊后5个月内死亡。甲状腺球蛋白mRNA的表达确定了该细胞系的甲状腺上皮起源。
该细胞来源于人甲状腺癌组织,代表转移性PTC、FTC和ATC。它们的基因组成反映了在甲状腺癌中观察到的常见突变,如BRAF、RAS和PI3K基因的改变,这些基因激活了关键的信号通路。这使得C643细胞成为研究甲状腺癌发生发展机制的理想模型。C643细胞成为甲状腺癌研究的重要工具。此外C643细胞是测试潜在靶向治疗的重要资源。
将其纳入临床前研究有助于识别和评估特异性靶向甲状腺癌信号通路改变的新化合物。通过准确地代表人类甲状腺癌,C643细胞有助于开发晚期甲状腺癌患者更有效的治疗方法。

种属

性别/年龄

/76

组织

甲状腺

疾病

 甲状腺未分化癌

细胞类型

 肿瘤细胞

形态学

上皮

生长方式

贴壁

倍增时间

大约23小时

培养基和添加剂

RPMI-1640(中乔新舟 货号:ZQ-200+10%胎牛血清(中乔新舟 货号:ZQ500-A+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0321

生物安全等级

BSL-1

STR位点信息

D5S818: 11,12

D13S317: 8,10

D7S820: 9,12

D16S539: 9,13

vWA: 15,17

THO1: 9.3,10

Amelogenin: X,Y

TPOX: 11,12

CSF1PO: 10,11

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

  ***

基因表达

  ***

供应限制

仅供科研使用

货号

ZQ0321

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


论文标题: Co-Delivery of 131I and Prima-1 by Self-Assembled CD44-Targeted Nanoparticles for Anaplastic Thyroid Carcinoma Theranostics
DOI: 10.1002/adhm.202001029
发表时间: 2020-12-16
期刊: Advanced Healthcare Materials
影响因子: 7.367
货号: ZQ0321
产品名称: C643 ATC cells
原文链接: https://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202001029


论文标题: LncRNA PVT1 Acts as a Tumor Promoter in Thyroid Cancer and Promotes Tumor Progression by Mediating miR-423-5p-PAK3
DOI: 10.2147/CMAR.S283443
发表时间: 2020-12-30
期刊: Cancer Management and Research
影响因子: 2.886
货号: ZQ0321
产品名称: C643 cells

原文链接: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779291/



PubMed=2848260; DOI=10.1073/pnas.85.23.9302
Heldin N.-E., Gustavsson B., Claesson-Welsh L., Hammacher A., Mark J., Heldin C.-H., Westermark B.
Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line.
Proc. Natl. Acad. Sci. U.S.A. 85:9302-9306(1988)


PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)


PubMed=17465858; DOI=10.1089/thy.2006.0246
Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E., Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.
Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
Thyroid 17:289-301(2007)


PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)


PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)


PubMed=19087340; DOI=10.1186/1471-2407-8-371
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371.1-371.11(2008)


PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)


PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)


PubMed=25365311; DOI=10.1210/jc.2014-2359
Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T., Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S., Liu L.-Z., Tan K.T., Chang W.J., Yang H., Ogawa S., Koeffler H.P.
Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.
J. Clin. Endocrinol. Metab. 100:725-735(2015)


PubMed=26680454; DOI=10.1186/s12885-015-1955-9
Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y.-J., Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.
The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
BMC Cancer 15:984.1-984.11(2015)


PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)


PubMed=31368081; DOI=10.1007/s12020-019-02009-5
Pinto A.T., Pojo M., Simoes-Pereira J., Roque R., Saramago A., Roque L., Martins C., Andre S., Cabecadas J., Leite V., Cavaco B.M.
Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
Endocrine 66:288-300(2019)



公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号